{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T15:01:30Z","timestamp":1774364490312,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00108-026-02078-5","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T13:18:22Z","timestamp":1773407902000},"page":"383-389","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neue Wege der Interdisziplinarit\u00e4t: Innere Medizin trifft auf Humangenetik","New ways in interdisciplinarity: internal medicine meets human genetics"],"prefix":"10.1007","volume":"67","author":[{"given":"Lars","family":"M\u00f6ller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann-Kathrin","family":"Sch\u00f6rding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"N\u00f6then","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Mack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Neubauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"2078_CR1","first-page":"1497","volume":"132","author":"P Nowell","year":"1960","unstructured":"Nowell\u00a0P, Hungeford\u00a0D (1960) A minute chromosome in human chronic granulocytic leukemia. Science 132:1497\u20131497","journal-title":"Science"},{"key":"2078_CR2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/306239a0","volume":"306","author":"N Heisterkamp","year":"1983","unstructured":"Heisterkamp\u00a0N, Stephenson\u00a0JR, Groffen\u00a0J, Hansen\u00a0PF, Deklein\u00a0A, Bartram\u00a0CR et\u00a0al (1983) Localization of the c\u2011abl oncogene adjacent to a translocation breakpoint in chronic myelogenous leukemia. Nature (Lond) 306:239\u2013242","journal-title":"Nature (Lond)"},{"key":"2078_CR3","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/300765a0","volume":"3000","author":"A de Klein","year":"1982","unstructured":"de Klein\u00a0A, Geurts van Kessel\u00a0A, Grosveld\u00a0GC, Bartram\u00a0CR, Hagemeijer\u00a0A, Bootsma\u00a0D et\u00a0al (1982) A cellular oncogene (c-abl) is translocated to the Philadelphia chromosome in chronic myelogenous leukemia. Nature (Lond) 3000:765\u2013767","journal-title":"Nature (Lond)"},{"key":"2078_CR4","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1126\/science.2406902","volume":"247","author":"GQ Daley","year":"1990","unstructured":"Daley\u00a0GQ, Van Etten\u00a0RA, Baltimore\u00a0D (1990) Induction of chronic myelogeneous leukemia in mice by the p210{Bcr\/abl} gene of the philadelphia chromosome. Science 247:824\u2013830","journal-title":"Science"},{"issue":"14","key":"2078_CR5","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker\u00a0BJ, Talpaz\u00a0M, Resta\u00a0DJ, Peng\u00a0B, Buchdunger\u00a0E, Ford\u00a0JM et\u00a0al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344(14):1031\u20131037","journal-title":"N Engl J Med"},{"issue":"14","key":"2078_CR6","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker\u00a0BJ, Sawyers\u00a0CL, Kantarjian\u00a0H, Resta\u00a0DJ, Reese\u00a0SF, Ford\u00a0JM et\u00a0al (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344(14):1038\u20131042","journal-title":"N Engl J Med"},{"issue":"6","key":"2078_CR7","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3324\/haematol.2016.142877","volume":"101","author":"R Hehlmann","year":"2016","unstructured":"Hehlmann\u00a0R (2016) Innovation in hematology. Perspectives: CML 2016. Haematologica 101(6):657\u2013659","journal-title":"Haematologica"},{"issue":"11","key":"2078_CR8","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1038\/leu.2017.253","volume":"31","author":"R Hehlmann","year":"2017","unstructured":"Hehlmann\u00a0R, Lauseker\u00a0M, Saussele\u00a0S, Pfirrmann\u00a0M, Krause\u00a0S, Kolb\u00a0HJ et\u00a0al (2017) Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia 31(11):2398\u2013406","journal-title":"Leukemia"},{"issue":"8060","key":"2078_CR9","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/s41586-025-08817-2","volume":"640","author":"AE Kamizela","year":"2025","unstructured":"Kamizela\u00a0AE, Leongamornlert\u00a0D, Williams\u00a0N, Wang\u00a0X, Nyamondo\u00a0K, Dawson\u00a0K et\u00a0al (2025) Timing and trajectory of BCR::ABL1-driven chronic myeloid leukaemia. Nature 640(8060):982\u2013990","journal-title":"Nature"},{"issue":"2","key":"2078_CR10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ccell.2023.12.016","volume":"42","author":"P C","year":"2024","unstructured":"Pacini\u00a0C, Duncan\u00a0E, Gon\u00e7alves\u00a0E, Gilbert\u00a0J, Bhosle\u00a0S, Horswell\u00a0S, et\u00a0al. A comprehensive clinically informed map of dependencies in cancer cells and framework for target prioritization. Cancer Cell. 2024;42(2):301\u201316.e9","journal-title":"Cancer Cell"},{"issue":"3","key":"2078_CR11","first-page":"211","volume":"65","author":"L Ruge","year":"2024","unstructured":"Ruge\u00a0L, John\u00a0F, Scharpenseel\u00a0H, Wolf\u00a0J (2024) Advances in the targeted treatment of non-small cell lung cancer. Inn Med (Heidelb) 65(3):211\u2013219","journal-title":"Inn Med (Heidelb)"},{"issue":"52","key":"2078_CR12","first-page":"E11323","volume":"114","author":"GS Hones","year":"2017","unstructured":"Hones\u00a0GS, Rakov\u00a0H, Logan\u00a0J, Liao\u00a0XH, Werbenko\u00a0E, Pollard\u00a0AS et\u00a0al (2017) Noncanonical thyroid hormone signaling mediates cardiometabolic effects in vivo. Proceedings of the National Academy of Sciences of the United States of America 114(52):E11323\u2013E11332","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"2078_CR13","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1210\/me.2008-0311","volume":"23","author":"O Araki","year":"2009","unstructured":"Araki\u00a0O, Ying\u00a0H, Zhu\u00a0XG, Willingham\u00a0MC, Cheng\u00a0SY (2009) Distinct dysregulation of lipid metabolism by unliganded thyroid hormone receptor isoforms. Mol Endocrinol 23(3):308\u2013315","journal-title":"Mol Endocrinol"},{"key":"2078_CR14","doi-asserted-by":"crossref","unstructured":"Pappa T, Refetoff S. Resistance to Thyroid Hormone Beta: A\u00a0Focused Review. Frontiers in endocrinology. 2021;12(316).","DOI":"10.3389\/fendo.2021.656551"},{"issue":"7","key":"2078_CR15","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1016\/j.bbagen.2012.08.005","volume":"1830","author":"AM Dumitrescu","year":"2013","unstructured":"Dumitrescu\u00a0AM, Refetoff\u00a0S (2013) The syndromes of reduced sensitivity to thyroid hormone. Biochimica et biophysica acta 1830(7):3987\u20134003","journal-title":"Biochimica et biophysica acta"},{"issue":"7","key":"2078_CR16","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1210\/jc.2016-3671","volume":"102","author":"I Campi","year":"2017","unstructured":"Campi\u00a0I, Cammarata\u00a0G, Bianchi Marzoli\u00a0S, Beck-Peccoz\u00a0P, Santarsiero\u00a0D, Dazzi\u00a0D et\u00a0al (2017) Retinal Photoreceptor Functions Are Compromised in Patients With Resistance to Thyroid Hormone Syndrome (RTH\u03b2). J\u00a0Clin Endocrinol Metab 102(7):2620\u20132627","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2078_CR17","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1089\/thy.2020.0651","volume":"31","author":"C Chaves","year":"2021","unstructured":"Chaves\u00a0C, Bruinstroop\u00a0E, Refetoff\u00a0S, Yen\u00a0PM, Anselmo\u00a0J (2021) Increased Hepatic Fat Content in Patients with Resistance to Thyroid Hormone Beta. Thyroid 31(7):1127\u20131134","journal-title":"Thyroid"},{"issue":"5","key":"2078_CR18","doi-asserted-by":"publisher","first-page":"e2005","DOI":"10.1210\/clinem\/dgab002","volume":"106","author":"C Moran","year":"2021","unstructured":"Moran\u00a0C, McEniery\u00a0CM, Schoenmakers\u00a0N, Mitchell\u00a0C, Sleigh\u00a0A, Watson\u00a0L et\u00a0al (2021) Dyslipidemia, Insulin Resistance, Ectopic Lipid Accumulation, and Vascular Function in Resistance to Thyroid Hormone \u03b2. J\u00a0Clin Endocrinol Metab 106(5):e2005\u2013e14","journal-title":"J Clin Endocrinol Metab"},{"key":"2078_CR19","doi-asserted-by":"crossref","unstructured":"Zhou J, Tripathi M, Ho JP, Widjaja AA, Shekeran SG, Camat MD, et\u00a0al. Thyroid Hormone Decreases Hepatic Steatosis, Inflammation, and Fibrosis in a\u00a0Dietary Mouse Model of Nonalcoholic Steatohepatitis. Thyroid. 2022.","DOI":"10.1089\/thy.2021.0621"},{"issue":"2","key":"2078_CR20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.atherosclerosis.2013.07.056","volume":"230","author":"R Taub","year":"2013","unstructured":"Taub\u00a0R, Chiang\u00a0E, Chabot-Blanchet\u00a0M, Kelly\u00a0MJ, Reeves\u00a0RA, Guertin\u00a0MC et\u00a0al (2013) Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-beta agonist. Atherosclerosis 230(2):373\u2013380","journal-title":"Atherosclerosis"},{"issue":"10","key":"2078_CR21","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1021\/jm4019299","volume":"57","author":"MJ Kelly","year":"2014","unstructured":"Kelly\u00a0MJ, Pietranico-Cole\u00a0S, Larigan\u00a0JD, Haynes\u00a0NE, Reynolds\u00a0CH, Scott\u00a0N et\u00a0al (2014) Discovery of 2\u2011[3,5-dichloro-4-(5-isopropyl-6-oxo\u20111,6\u2011dihydropyridazin-3-yloxy)phenyl]-3,5-dio xo\u20112,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor beta agonist in clinical trials for the treatment of dyslipidemia. Journal of medicinal chemistry 57(10):3912\u20133923","journal-title":"Journal of medicinal chemistry"},{"key":"2078_CR22","doi-asserted-by":"crossref","unstructured":"H\u00f6nes GS, Sivakumar RG, Hoppe C, K\u00f6nig J, F\u00fchrer D, Moeller LC. Cell-Specific Transport and Thyroid Hormone Receptor Isoform Selectivity Account for Hepatocyte-Targeted Thyromimetic Action of MGL-3196. International journal of molecular sciences [Internet]. 2022; 23(22).","DOI":"10.3390\/ijms232213714"},{"issue":"11","key":"2078_CR23","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","volume":"29","author":"SA Harrison","year":"2023","unstructured":"Harrison\u00a0SA, Taub\u00a0R, Neff\u00a0GW, Lucas\u00a0KJ, Labriola\u00a0D, Moussa\u00a0SE et\u00a0al (2023) Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nature medicine 29(11):2919\u20132928","journal-title":"Nature medicine"},{"issue":"6","key":"2078_CR24","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison\u00a0SA, Bedossa\u00a0P, Guy\u00a0CD, Schattenberg\u00a0JM, Loomba\u00a0R, Taub\u00a0R et\u00a0al (2024) A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med 390(6):497\u2013509","journal-title":"N Engl J Med"},{"issue":"3","key":"2078_CR25","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"F Tacke","year":"2024","unstructured":"Tacke\u00a0F, Horn\u00a0P, Wai-Sun Wong\u00a0V, Ratziu\u00a0V, Bugianesi\u00a0E, Francque\u00a0S et\u00a0al (2024) EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Journal of hepatology 81(3):492\u2013542","journal-title":"Journal of hepatology"},{"key":"2078_CR26","unstructured":"Younossi ZM, Zelber-Sagi S, Lazarus JV, Wong VW, Yilmaz Y, Duseja A, et\u00a0al. Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis. Gastroenterology. 2025."},{"key":"2078_CR27","doi-asserted-by":"crossref","unstructured":"Hones GS, Kerp H, Hoppe C, Kowalczyk M, Zwanziger D, Baba HA, et\u00a0al. Canonical Thyroid Hormone Receptor beta Action Stimulates Hepatocyte Proliferation in Male Mice. Endocrinology. 2022;163(3).","DOI":"10.1210\/endocr\/bqac003"},{"issue":"11","key":"2078_CR28","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1038\/s41591-023-02602-2","volume":"29","author":"TJ Kendall","year":"2023","unstructured":"Kendall\u00a0TJ, Jimenez-Ramos\u00a0M, Turner\u00a0F, Ramachandran\u00a0P, Minnier\u00a0J, McColgan\u00a0MD et\u00a0al (2023) An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease. Nature medicine 29(11):2939\u20132953","journal-title":"Nature medicine"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02078-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-026-02078-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02078-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T14:15:19Z","timestamp":1774361719000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-026-02078-5"}},"subtitle":["Wenn H\u00e4ufiges selten und Seltenes h\u00e4ufig wird","When frequent conditions become rare and rare conditions become frequent"],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2078"],"URL":"https:\/\/doi.org\/10.1007\/s00108-026-02078-5","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"L.\u00a0M\u00f6ller, A.-K.\u00a0Sch\u00f6rding, F.\u00a0Kaiser, M.\u00a0N\u00f6then, E.\u00a0Mack und A.\u00a0Neubauer geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}